Article
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2009
Okabe Takafumi, Okamoto Isamu, Tsukioka Sayaka, Uchida Junji, Hatashita Erina, Yamada Yuki, Yoshida Takeshi, Nishio Kazuto, Fukuoka Masahiro, Jänne Pasi A, Nakagawa Kazuhiko
Abstract excerpt
PURPOSE: Most non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib, but they almost invariably develop resistance to these drugs. A secondary mutation in EGFR (T790M) and amplification of the MET proto-oncogene have been identified as mechanisms of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.